Table 1 Characteristics of studies included in meta-analysis
Author | Geographic area | Year | Study period | Study design | No.of patients | Gender(M/F) | Median age(y) | Clinical Stage | Histology types (SCC/Other) | Chemotherapy regimens | Radiation technology | Radiation Dose groups | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Minsky [6] | USA | 2002 | 1995–1999 | Prospective (Phase III) | 218 | 154/64 | 64 | II-III | 187/31 | PF | 3DRT | 64.8Gy 50.4Gy | 5 |
Clavier [12] | France | 2011 | 2003–2006 | Retrospective | 143 | 118/25 | – | I-IVa | 113/30 | PF | 3DRT | 66 Gy 50Gy | 7 |
Suh [13] | Korea | 2014 | 1998–2008 | Retrospective | 126 | 117/9 | 66 | II-III | 117/9 | PF | 3DRT | >60Gy(60–75.6Gy) <=60Gy(45–59.4Gy) | 7 |
Chen [14] | China | 2016 | 2008–2013 | Retrospective | 648 | 619/29 | – | I-IV | 648/0 | CCRT | 3D-IMRT | >60Gy 50.4Gy | 8 |
Kim [15] | Korea | 2017 | 1994–2013 | Retrospective | 236 | 226/10 | 66 | II-III | 230/6 | PF | 3D-IMRT | > = 60Gy <60Gy | 8 |
Deng [16] | China | 2017 | 2010–2014 | Retrospective | 139 | 95/44 | 67 | I-III | 139/0 | TPF | 3D-IMRT | > 59.4Gy 50.4Gy | 8 |
Chang [17] | Taiwan area | 2017 | 2006–2014 | Retrospective | 2061 | 1958/103 | 57 | I-III | 2061/0 | CCRT | IMRT | > = 60Gy(60-72Gy) <60Gy(45–59.4Gy) | 7 |
Chen [18] | China | 2018 | 2004–2013 | Retrospective | 165 | 139/26 | 55 | I-IV | 165/0 | CCRT | 2/3D-IMRT | <60Gy(56–60) 60-65Gy >65Gy | 5 |